Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.77 USD | +2.82% | +4.67% | +48.49% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 634M |
---|---|---|---|---|---|
Net income 2024 * | -142M | Net income 2025 * | -173M | EV / Sales 2024 * | - |
Net cash position 2024 * | 105M | Net cash position 2025 * | 137M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-4.26
x | P/E ratio 2025 * |
-3.98
x | Employees | 28 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.47% |
Latest transcript on Mineralys Therapeutics, Inc.
1 day | +2.82% | ||
1 week | +4.67% | ||
1 month | -0.23% | ||
3 months | -16.75% | ||
6 months | +77.36% | ||
Current year | +48.49% |
Managers | Title | Age | Since |
---|---|---|---|
Jon Congleton
CEO | Chief Executive Officer | 60 | 20-10-31 |
Adam Levy
DFI | Director of Finance/CFO | 46 | 22-02-28 |
Jessica Ibbitson
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 56 | 21-01-31 | |
Glenn Sblendorio
BRD | Director/Board Member | 68 | 23-09-12 |
Daphne Karydas
BRD | Director/Board Member | 49 | 23-09-12 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +3.86% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 12.77 | +2.82% | 207,540 |
24-05-30 | 12.42 | +0.89% | 95,366 |
24-05-29 | 12.31 | +1.23% | 61,077 |
24-05-28 | 12.16 | -0.33% | 82,538 |
24-05-24 | 12.2 | -0.25% | 44,910 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+48.49% | 634M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- MLYS Stock